CMXHF - CSL Limited gets CDC recommendation for seasonal influenza vaccine

Seqirus, a unit of Australian biotech CSL Limited (OTCPK:CSLLY) (OTCPK:CMXHF), announced that a group of independent experts of the U.S. CDC added its Fluad Quadrivalent shot as a preferentially recommended seasonal influenza vaccine for those aged 65 years and older. The decision of the CDC’s Advisory Committee on Immunization Practices (ACIP) was based on the clinical benefits of the vaccine compared to standard egg-based influenza vaccines, the company added. Fluad Quadrivalent is designed to protect against four strains of seasonal influenza annually. A preferential recommendation helps guide both healthcare providers and patients on the standard of care for this at-risk age group, Dave Ross, Vice President, North America Commercial Operations, Seqirus said. One of the largest influenza vaccine providers in the world, Seqirus reported ~20% YoY growth in seasonal influenza vaccine sales in the second half of 2021.

For further details see:

CSL Limited gets CDC recommendation for seasonal influenza vaccine